Transaction DateRecipientSharesTypePriceValue
9th September 2020Renato Skerlj5,834Open or private sale$8.05$46,963.70
9th September 2020Paula Ragan8,840Open or private sale$8.04$71,073.60
9th September 2020Derek M Meisner8,334Open or private sale$8.05$67,088.70
2nd September 2020Paula Ragan2,400Open or private sale$7.99$19,176.00
17th August 2020Adam S. Mostafa16,250Grant/award etc.$0.00
17th August 2020Derek M Meisner12,500Grant/award etc.$0.00
17th August 2020Renato Skerlj8,750Grant/award etc.$0.00
17th August 2020Paula Ragan44,825Grant/award etc.$0.00
14th August 2020Derek M Meisner12,500Grant/award etc.$0.00
14th August 2020Renato Skerlj8,750Grant/award etc.$0.00
Arsanis
Arsanis logo

Biotechnology company engages in developing human antibodies for treating infectious diseases. Operates as a biotechnology company which engages indeveloping human antibodies.

Ticker: ASNS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1501697
Employees: 15
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $104 M (0%)
Assets, Current: $110 M (-14%)
Property, Plant and Equipment, Net: $421 Th (0%)
Other Assets, Noncurrent: $3 M (78%)
Assets: $143 M (-11%)
Accounts Payable, Current: $2 M (-11%)
Accrued Liabilities, Current: $8 M (0%)
Liabilities, Current: $11 M (14%)
Other Liabilities, Noncurrent: $26 Th (62%)
Liabilities: $38 M (19%)
Common Stock, Value, Issued: $16 Th (0%)
Additional Paid in Capital, Common Stock: $263 M (0%)
Retained Earnings (Accumulated Deficit): $158 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $119 Th (0%)
Stockholders' Equity (Parent): $105 M (0%)
Liabilities and Equity: $143 M (-11%)
Revenue: $0 (-100%)
Research and Development: $9 M (-48%)
General and Administrative Expenses: $5 M (-46%)
Operating Income/Loss: $15 M (-41%)
Other Income, net: $486 Th (-45%)
Provision for income taxes: $0 (-100%)